New combo therapy targets stubborn nasopharyngeal cancer in phase 3 trial

This study tests whether adding chemotherapy to immunotherapy works better than immunotherapy alone for people with advanced nasopharyngeal cancer whose cancer did not fully respond to initial treatment. About 516 adults aged 18-65 with stage II-III disease will receive either the drug adebrelimab alone or adebrelimab plus capecitabine. The goal is to see which approach better prevents the cancer from returning or spreading.